Madrigal Pharmaceuticals, Inc. $MDGL Stock Position Lessened by Candriam S.C.A.

Key Points

• Candriam S.C.A. cut its Madrigal Pharmaceuticals stake by 4.5% in the third quarter, selling 3,279 shares; it retained 68,842 shares, valued at about $34.8 million.
• Madrigal reported quarterly EPS of $1.83, versus analysts’ expectation of a $1.09 loss, and revenue of $431.3 million, above the $404.2 million estimate.
• Analysts maintain a broadly positive outlook: the stock has a “Moderate Buy” consensus rating and an average price target of $706.87. New real-world Rezdiffra data also reported improvements in liver stiffness and cardiometabolic markers.

Candriam S.C.A. trimmed its position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 4.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 68,842 shares of the biopharmaceutical company's stock after selling 3,279 shares during the quarter. Candriam S.C.A. owned approximately 0.30% of Madrigal Pharmaceuticals worth $34,820,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the company. Jupiter Topco LLC bought a new stake in shares of Madrigal Pharmaceuticals during the second quarter worth $1,039,650,000. Paulson & CO. Inc. bought a new position in shares of Madrigal Pharmaceuticals in the second quarter valued at about $719,524,000. BlackRock Inc. bought a new position in shares of Madrigal Pharmaceuticals in the second quarter valued at about $644,753,000. Janus Henderson Group PLC raised its holdings in shares of Madrigal Pharmaceuticals by 27.4% in the first quarter. Janus Henderson Group PLC now owns 2,018,647 shares of the biopharmaceutical company's stock valued at $1,051,727,000 after buying an additional 433,804 shares during the last quarter. Finally, William Blair Investment Management LLC acquired a new position in Madrigal Pharmaceuticals during the 2nd quarter worth about $174,038,000. Institutional investors and hedge funds own 98.50% of the company's stock.

More Madrigal Pharmaceuticals News

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

• Positive Sentiment: Multiple real-world studies presented at AASLD reported improvements in liver stiffness and cardiometabolic health markers among patients treated with Rezdiffra, supporting the drug’s real-world potential. Rezdiffra real-world data
• Positive Sentiment: Madrigal’s latest quarterly results beat estimates: EPS was $1.83 versus consensus of a $1.09 loss, and revenue of $431.3 million exceeded the $404.2 million estimate. Madrigal stock jumps after earnings beat
• Positive Sentiment: HC Wainwright reiterated a Strong-Buy rating and projected rising EPS through 2030; Canaccord Genuity also raised its price target to $633 and maintained a Buy rating. These forecasts point to optimism about future growth, though they are analyst expectations, not guarantees.
• Neutral Sentiment: General Counsel Shannon Kelley sold 1,077 shares for about $430,800 under a pre-arranged Rule 10b5-1 plan. Kelley retained 10,397 shares, which may temper concern about the sale.
• Negative Sentiment: Several law firms announced investigations into potential securities-law violations after Madrigal’s November 3 quarterly filing. These are investigations and investor solicitations—not findings of wrongdoing—but could create legal and reputational uncertainty. Securities investigation announcement

Madrigal Pharmaceuticals Price Performance

Madrigal Pharmaceuticals stock opened at $399.63 on Monday. The business's 50-day simple moving average is $486.74 and its 200 day simple moving average is $497.41. The stock has a market cap of $9.28 billion, a price-to-earnings ratio of -66.83 and a beta of -0.98. Madrigal Pharmaceuticals, Inc. has a 12-month low of $353.54 and a 12-month high of $615.00. The company has a quick ratio of 2.78, a current ratio of 3.05 and a debt-to-equity ratio of 0.54.

Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last announced its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported $1.83 earnings per share for the quarter, topping the consensus estimate of ($1.09) by $2.92. The firm had revenue of $431.27 million during the quarter, compared to analysts' expectations of $404.17 million. Madrigal Pharmaceuticals had a negative return on equity of 27.08% and a negative net margin of 10.89%. During the same period in the previous year, the business posted ($5.08) EPS. As a group, research analysts anticipate that Madrigal Pharmaceuticals, Inc. will post -2.08 earnings per share for the current year.

Insider Activity

In other news, CEO William Sibold sold 6,362 shares of the firm's stock in a transaction dated Wednesday, September 9th. The shares were sold at an average price of $535.59, for a total value of $3,407,423.58. Following the transaction, the chief executive officer owned 202,967 shares of the company's stock, valued at approximately $108,707,095.53. This trade represents a 3.04% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Bros. Advisors Lp Baker purchased 76,140 shares of the stock in a transaction dated Friday, November 6th. The shares were acquired at an average price of $384.32 per share, with a total value of $29,262,124.80. Following the transaction, the director owned 2,040,682 shares in the company, valued at $784,274,906.24. This trade represents a 3.88% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last quarter, insiders have sold 13,324 shares of company stock valued at $7,011,982. 17.60% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on MDGL shares. Wolfe Research raised shares of Madrigal Pharmaceuticals from a "peer perform" rating to an "outperform" rating and set a $605.00 price objective on the stock in a report on Tuesday, August 4th. Citigroup boosted their target price on shares of Madrigal Pharmaceuticals from $725.00 to $760.00 and gave the stock a "buy" rating in a research note on Tuesday, November 3rd. UBS Group reissued a "buy" rating and set a $735.00 price target on shares of Madrigal Pharmaceuticals in a research note on Wednesday, October 14th. Canaccord Genuity Group increased their price target on shares of Madrigal Pharmaceuticals from $612.00 to $633.00 and gave the company a "buy" rating in a research note on Wednesday, November 4th. Finally, Wells Fargo & Company started coverage on shares of Madrigal Pharmaceuticals in a report on Monday, July 27th. They issued an "overweight" rating and a $685.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Madrigal Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $706.87.

Madrigal Pharmaceuticals Profile

Madrigal Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. The company is headquartered in Conshohocken, Pennsylvania.

Its lead product, Rezdiffra (resmetirom), is a thyroid hormone receptor-beta agonist. The U.S. Food and Drug Administration approved Rezdiffra in 2024 for use with diet and exercise in adults with noncirrhotic MASH and moderate-to-advanced liver fibrosis.

Madrigal's work centers on advancing medicines for liver disease, with Rezdiffra serving as its first approved therapy.

Want to see what other hedge funds are holding MDGL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.